痛风合并2型糖尿病患者启用SGLT2抑制剂后痛风相关用药变化:基于人群的目标试验模拟研究
该研究采用目标试验模拟方法,在痛风合并2型糖尿病人群中比较启用SGLT2抑制剂与DPP-4抑制剂(或GLP-1受体激动剂)后痛风相关用药的差异。结果显示,SGLT2抑制剂组别嘌醇起始风险更低(HR 0.62,95%CI 0.52-0.73),且高剂量糖皮质激素、NSAIDs、秋水仙碱及利尿剂的 dispensing 率均更低。提示SGLT2抑制剂可能减少痛风相关用药暴露。
要点
- SGLT2抑制剂组高剂量糖皮质激素、NSAIDs、秋水仙碱及利尿剂 dispensing 率均更低。
- 基线使用利尿剂者中SGLT2抑制剂与别嘌醇起始的关联更强(交互P=0.03)。
核心结论
- 在痛风合并2型糖尿病患者中,SGLT2抑制剂可能减少痛风相关用药(别嘌醇、高剂量糖皮质激素、NSAIDs、秋水仙碱)及利尿剂的使用。
- 该效应可能降低该高危人群暴露于NSAIDs和糖皮质激素的心血管-肾脏-代谢有害作用。
研究设计与样本
- 基于一般人群数据库的目标试验模拟研究,纳入痛风合并2型糖尿病成人26739例(平均年龄66岁),67%存在多重用药。
- 采用Cox比例风险模型和Poisson回归,以逆概率治疗加权模拟随机分配至SGLT2抑制剂或DPP-4抑制剂(主要对照)/GLP-1受体激动剂(替代对照)。
- 在电子健康记录数据集中重复分析,并进一步校正血清尿酸和BMI。
主要发现
- SGLT2抑制剂起始者别嘌醇起始风险低于DPP-4抑制剂起始者,HR 0.62(95%CI 0.52-0.73)。
- 基线使用利尿剂者中该关联更强(交互P=0.03),且与GLP-1受体激动剂比较及校正血清尿酸和BMI后结果持续。
- SGLT2抑制剂与高剂量糖皮质激素、NSAIDs、秋水仙碱、利尿剂 dispensing 率更低相关,率比分别为0.78(95%CI 0.74-0.83)、0.85(95%CI 0.80-0.92)、0.87(95%CI 0.83-0.92)、0.87(95%CI 0.85-0.89)。
临床怎么用
- 对痛风合并2型糖尿病患者,选择SGLT2抑制剂可能减少后续别嘌醇起始及抗炎药、利尿剂使用。
- 该作用在基线使用利尿剂的患者中可能更明显。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) lower serum urate and are associated with a lower risk of recurrent gout flares. We used target trial emulation to compare rates of allopurinol initiation and use of anti-inflammatories (high-dose glucocorticoids, nonsteroidal anti-inflammatory drugs [NSAIDs], colchicine) and diuretics (prototypic serum urate-raising medication) among patients with gout using SGLT2is versus dipeptidyl peptidase 4 inhibitors (DPP-4is) (primary comparator), with glucagon-like peptide 1 receptor agonists (GLP-1RAs) as an alternative comparator. RESEARCH DESIGN AND METHODS: From a general population database, we identified patients with gout and comorbid type 2 diabetes and used Cox proportional hazards and Poisson regressions with inverse probability of treatment weighting to emulate randomization to SGLT2i or DPP-4i/GLP-1RA. We also replicated the analysis in an electronic health record data set with further adjustment for serum urate and BMI. RESULTS: Among 26,739 adults with gout and type 2 diabetes (mean age 66 years), 67% had polypharmacy. Allopurinol initiation was lower among SGLT2i initiators than DPP-4i, with a hazard ratio of 0.62 (95% CI 0.52-0.73). Associations were stronger among those using diuretics at baseline (P for interaction = 0.03) and persisted when comparing SGLT2i with GLP-1RA and accounting for serum urate and BMI in the secondary data set. SGLT2i was also associated with lower rates of high-dose glucocorticoid, NSAID, colchicine, and diuretic dispensing, with rate ratios of 0.78 (95% CI 0.74-0.83), 0.85 (95% CI 0.80-0.92), 0.87 (95% CI 0.83-0.92), and 0.87 (95% CI 0.85-0.89), respectively. CONCLUSIONS: For patients with gout and type 2 diabetes, SGLT2is may reduce gout-related medication use, which could, in turn, reduce exposure to the harmful cardiovascular-kidney-metabolic effects of NSAIDs and glucocorticoids in this high-risk population.
引用
- McCormick N, Burrack N, Yokose C, et al. Gout-Related Medication Use After Initiating Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies. Diabetes Care. 2026. PMID: 41615420. doi:10.2337/dc25-1713
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。